From: Sultan Sulayem To: [email protected] Subject: Praluent's sales could eclipse $7 billion. Date: Sun, 09 Aug 2015 18:11:11 +0000 Will Regeneron's New Drug Break The Bank? Regeneron and Sanoties newly-lau

es could eclipse $7 billion. Date: Sun, 09 Aug 2015 18:11:11 +0000 Will Regeneron's New Drug Break The Bank? Regeneron and Sanoties newly-launched Praluent could cause healthcare costs to soar. Todd Campbell TMFEBCapital Aug 5, 2015 at 8:03AM ,,,Money Inside Pills Flickr User Chris Potter Source: Fl

ainst heart disease — and the approval is a triumph for Regeneron Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost down the line. "Obvi

low me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page. Loading... Loading... The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being ad

had heart attacks or strokes, who are already taking the maximum dose of a statin they can tolerate. Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a year, for either of two doses, 75 milligrams or 150 mgs. It’s likely that insurance companies w

had heart attacks or strokes, who are already taking the maximum dose of a statin they can tolerate. Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a year, for either of two doses, 75 milligrams or 150 mgs. It’s likely that insurance companies w